Elbaor v. Smith

¶1OPINION

¶2In this medical malpractice case we consider: 1) whether the trial court should have submitted to the jury a requested issue concerning the plaintiff’s contributory negligence; and 2) whether Mary Carter agreements are void as contrary to public policy. The trial court rendered judgment in favor of the plaintiff, and the court of appeals affirmed. 845 S.W.2d 282. We hold that the trial court committed reversible error in refusing to submit an issue on the plaintiff’s contributory negligence. We further hold that Mary Carter agreements are void as against public policy.1 We thus reverse the judgment of the court of appeals and remand this cause to the trial court for a new trial.

¶3I.

¶4At 2:00 a.m. on May 8, 1985, Carole Smith was seriously injured in a single-vehicle accident when the Corvette she was driving left the highway and collided with a tree. She received emergency treatment at the Dallas/Fort Worth Medical Center-Grand Prairie (“D/FW Medical Center”) *242from Dr. Abraham Syrquin for multiple injuries including a compound fracture of her left ankle. In an effort to stop the bleeding, Dr. Syrquin performed emergency surgery closing the ankle wound. Ms. Smith remained under Dr. Syrquin’s treatment for eight days at D/FW Medical Center after which time she was transferred to the care of Dr. James Elbaor, an orthopedic surgeon, at Arlington Community Hospital (“ACH”).

¶5While Ms. Smith was at ACH, she was treated by a team of physicians including Dr. Elbaor, Dr. Joseph Stephens, a plastic surgeon, and Dr. Bienvenido Gatmaitan, an infectious disease specialist. Upon admission to ACH, Ms. Smith was evaluated by Dr. Gatmaitan and placed on intravenous antibiotics. During the course of her stay, Dr. Stephens performed two debridements of the ankle wound.2 Although the issue of whether Ms. Smith’s ankle was infected was hotly contested at trial, Dr. Stephens’ progress notes following both debridement procedures indicated that there was no active infection present in the ankle. On June 8, Ms. Smith was transferred to the care of Dr. Wayne Burkhead at Baylor University Medical Center (“Baylor”). Four days after admission, Dr. Burkhead removed a two inch section of bone from Ms. Smith’s ankle. Ms. Smith received treatment from several orthopedic specialists over the next three years which ultimately led to the fusion of her ankle joint.

¶6Ms. Smith’s medical records from D/FW Medical Center and ACH indicate that she refused to cooperate with the instructions of her doctors and nurses. She frequently refused to take her antibiotics, and directed family members to remove weights from her femoral traction device. Some time later, Ms. Smith was transferred to another hospital for surgery to shorten and fuse the bone, leaving her permanently disabled.

¶7Ms. Smith filed suit against D/FW Medical Center, ACH, Drs. Syrquin, Elbaor, Stephens, and Gatmaitan. Sometime before trial, Ms. Smith entered into Mary Carter agreements with Dr. Syrquin, Dr. Stephens, and ACH.3 The Mary Carter agreements provided for payments to Ms. Smith of $350,000 from Dr. Syrquin, $75,000 from ACH, and $10 from Dr. Stephens. Under the terms of each agreement, the settling defendants were required to participate in the trial of the case. The agreements also contained pay-back provisions whereby Dr. Syrquin and ACH would be reimbursed all or part of the settlement money paid to Ms. Smith out of the recovery against Dr. Elb-aor.

¶8Ms. Smith nonsuited her claim against Dr. Gatmaitan and settled and dismissed her claim against D/FW Medical Center. Dr. Elbaor filed a cross claim against Dr. Stephens, Dr. Gatmaitan,4 Dr. Syrquin, and ACH. He alleged that in the event he was found liable to Ms. Smith, that he was entitled to contribution from these defendants. Furthermore, Dr. Elbaor requested that the trial court hold the Mary Carter agreements void as against public policy, and alternatively, to dismiss the settling defendants from the suit. The trial court denied this request. The suit proceeded to trial against Dr. Elbaor and the cross defendants.

¶9At trial, the jury found that Ms. Smith’s damages totalled $2,253,237.07, of which Dr. Elbaor was responsible for eighty-eight percent, and Dr. Syrquin for twelve percent. After deducting all credits for Dr. Syrquin’s percentage of causation and settlements with other defendants, the trial *243court rendered judgment against Dr. Elb-aor for $1,872,848.62.

¶10II.

¶11We first consider Dr. Elbaor’s assertion that the trial court erred by refusing to submit to the jury a question on Ms. Smith’s contributory negligence (along with questions addressing his own negligence and that of Drs. Syrquin and Stephens). The court of appeals held that the trial court’s refusal was not error because there was no evidence of Ms. Smith’s contributory negligence. 845 S.W.2d at 284. The court concluded that evidence of Ms. Smith’s refusal of antibiotics only entitled Dr. Elbaor to an instruction on Ms. Smith’s failure to mitigate damages.

¶12Rule 278 of the Texas Rules of Civil Procedure provides that:

[t]he court shall submit the questions, instructions and definitions in the form provided by Rule 277, which are raised by the written pleadings and evidence.

¶13This rule provides a substantive, non-discretionary directive to trial courts requiring them to submit requested questions to the jury if the pleadings and any evidence support them. To determine whether legally sufficient evidence supported Dr. Elb-aor’s contributory negligence submission, we must examine the record for evidence supporting Dr. Elbaor’s question and ignore all evidence to the contrary. See, e.g., Roy v. Howard-Glendale Funeral Home, 820 S.W.2d 844, 846 (Tex.App.—Houston [1st Dist.] 1991, writ denied) (“trial court is obligated to submit the question if the evidence [supporting question] amounts to more than a scintilla”); Times Herald Printing v. A.H. Belo Corp., 820 S.W.2d 206, 215 (Tex.App.—Houston [14th Dist.] 1991, no writ) (in reviewing evidence regarding refused question, appellate court “consider[ed] evidence most favorably in behalf of the complaining party”); Kerrville HRH, Inc. v. City of Kerrville, 803 S.W.2d 377, 383 (Tex.App.—San Antonio 1990, writ denied) (trial court “may refuse to submit a question only if no evidence exists to warrant its submission”); Bryan v. Dockery, 788 S.W.2d 447, 451 (Tex.App.—Houston [1st Dist.] 1990, no writ) (“evidence must be considered in favor of the party against whom the questions were refused and if it supports the question then it must be submitted”); Phillips Pipeline Co. v. Richardson, 680 S.W.2d 43, 48 (Tex.App.—El Paso 1984, no writ) (“evidence must be considered most favorably in behalf of the party against whom the issues were refused, and if there is any conflicting probative evidence in the record, those questions are for the jury’s determination”). A trial court may refuse to submit an issue only if no evidence exists to warrant its submission. Brown v. Goldstein, 685 S.W.2d 640, 641 (Tex.1985) (where evidence was conflicting, it is error to refuse submission of contributory negligence issues); Garza v. Alviar, 395 S.W.2d 821, 824 (Tex.1965) (contention that question should not have gone to jury only sustainable if no evidence supports question).

¶14In order to determine whether Dr. Elb-aor’s questions should have been presented to the jury, we must examine the record to see if there is some evidence that Ms. Smith’s refusal to take antibiotics arguably preceded the onset of infection in her ankle. If we find some evidence indicating that Ms. Smith may have been contribu-torily negligent, then we must conclude that the trial court should have submitted Dr. Elbaor’s requested contributory negligence question; and accordingly, we must reverse this cause and remand it for a new trial.

¶15A brief chronology of events will aid our analysis. After the accident on May 8, 1985, Ms. Smith was treated by Dr. Syr-quin at D/FW Medical Center for injuries to her left shoulder, femur, and ankle. On May 17, she was transferred to ACH and into the care of Drs. Elbaor, Stephens, and Gatmaitan. She remained under their care until she was transferred to Baylor on June 3.

¶16Shortly after Ms. Smith arrived at ACH, Dr. Gatmaitan rendered an initial diagnosis concluding that her ankle was infected, and *244he began treating her with intravenous antibiotics.5 Ms. Smith, however, did not exhibit symptoms typical of systemic infection. That is, as Dr. Stephens’ medical notes reveal, she had no fever and her ankle wound was dry and appeared to be healing. Dr. Elbaor’s notes of May 20 show that he decided to have Ms. Smith’s ankle debrided the following day in order to discover whether it was infected. He also noted that there was no drainage from the ankle as would be typical of an infected wound. Dr. Stephens performed the first of two debridements on Ms. Smith’s ankle on May 21. His subsequent medical notes reveal that the wound was clean, healthy, and dry. And on May 26, he noted, regarding the ankle wound, that “I do not feel it is infected.” Dr. Stephens still thought the ankle healthy on May 30, just a few days before Ms. Smith transferred herself to Baylor; and he was contemplating performing a skin graft, which, as Dr. Elbaor testified, would have been unthinkable if there had been any sign of infection. The record contains evidence of Ms. Smith’s refusal of the antibiotics that were essential to prevent infection in her ankle.6 Ms. Smith began refusing antibiotics shortly after her admission to ACH.7 The administering nurse noted that Ms. Smith refused medication on May 20. And Dr. Elbaor’s assistant’s notes indicate that Ms. Smith was still refusing them on May 29, shortly before her transfer to Baylor. Dr. Joseph H. Gaines, a medical expert, testified that Ms. Smith had refused antibiotics at least six times while she was at ACH. As Dr. Elbaor testified, “you have to keep [antibiotics] at a certain level in the bloodstream and tissues to attack or cure any organisms that may be there.” He further noted that the failure to take antibiotics “can allow resistant organisms to grow.”

¶17The foregoing discussion reveals that the record contained some evidence that Ms. Smith’s ankle was not infected when she arrived at ACH on May 17, 1985. Further, the record indisputably indicates that Ms. Smith refused antibiotics, essential to the maintenance of her ankle’s health, throughout her stay at ACH. Taken together, this evidence amounts at least to some evidence supporting Dr. Elbaor’s assertion of Ms. Smith’s contributory negligence. Accordingly, the trial court should have submitted it to the jury. See Southwestern Bell Tel. Co. v. Thomas, 554 S.W.2d 672, 674 (Tex.1977) (trial court must submit issues if there is “some evidence” of contributory negligence).

¶18Dr. Elbaor properly preserved error regarding the trial court’s wrongful refusal of the contributory negligence questions, instructions, and definitions. He complained during the charge conference that the court’s submission failed to adequately account for Ms. Smith’s contributory negligence. He also submitted contributory negligence and proximate cause questions in “substantially correct wording” as required by Rule 278. See Placencio v. Allied Indus. Int’l Exch., 724 S.W.2d 20, 21 (Tex.1987).

¶19The court of appeals held that the evidence raised issues of failure to miti*245gate, but not contributory negligence. As we have observed, “[njegligence that merely increases or adds to the extent of the loss or injury occasioned by another’s negligence is not ... contributory negligence.” Kerby v. Abilene Christian College, 503 S.W.2d 526, 528 (Tex.1973). In Kerby, the plaintiff was driving a delivery truck with its sliding door open. He collided with a bus, the force of which threw him from the truck, causing him serious injuries. The trial court submitted a question on the driver’s contributory negligence. Id. at 527. This Court held that the trial court should have accounted for any increase in injury caused by the plaintiff driving with the door open through a mitigation of damages question, and not one of contributory negligence. For this reason, the dissent’s reliance on Kerbyis misplaced.

¶20Moreover, the instant case is fundamentally distinguishable from Kerby. Driving a delivery truck with its sliding door open is neither an intrinsically harmful act, nor is it a breach of a legal duty. However, the unusual act of refusing to take antibiotics, which a medical doctor has prescribed to preserve a patient’s health, plainly may cause harm. Additionally, it breaches a duty of cooperation which patients owe treating physicians who assume the duty to care for them. Ms. Smith was arguably free of infection when she arrived at ACH. She began breaching her duty to cooperate from the moment she arrived by refusing antibiotics, and she remained uncooperative throughout her stay at ACH. Ms. Smith’s refusal to take the antibiotics also constituted an inherently harmful act, because, as the testimony at trial demonstrated, refusing antibiotics can permit an infection to develop. Thus, her refusal of medication essential to maintaining her health created a fact issue as to whether she contributed to the infection that eventually afflicted her ankle.

¶21Furthermore, the Court in Kerbyheld that the plaintiff’s conduct of driving with the door open was not contributory negligence because it did not contribute to the accident; rather, it only increased the injuries suffered in the accident. In the present case, the “accident” equates to the medical problem complained of: Ms. Smith’s infected ankle. Her conduct arguably did contribute to the infection. In Kerby, there would have been a wreck, and a lawsuit, even if the plaintiff had kept the door of his truck closed. Here, there might have been no infection, and thus no claim of medical malpractice, had Ms. Smith followed her doctors’ instructions.

¶22The trial court improperly addressed Ms. Smith’s conduct through a mitigation of damages instruction. The plain language of Rule 278 bound the trial court to submit Dr. Elbaor’s question. Dr. Elbaor pleaded that Ms. Smith committed contributory negligence by refusing to take antibiotics while under his care at ACH, and he put on evidence at trial supporting his assertion that Ms. Smith’s refusal to take antibiotics contributed to her injury. Therefore, the trial court in this case failed to follow the directive of Rule 278. Instead, the trial court chose to account for Ms. Smith’s negligence by submitting an instruction on mitigation of damages which instructed the jury to exclude from its verdict any damages attributable to Ms. Smith’s negligence. This instruction contained no definition of negligence upon which the jury could have based its decision as to whether she was negligent. See Griffin v. Eakin, 656 S.W.2d 187, 190 (Tex.App.—Austin 1983, writ ref’d n.r.e.) (absence of negligence definition confuses jury burdened with resolving negligence question).8

¶23III.

¶24As previously noted, Ms. Smith entered into Mary Carter agreements with Dr. Syr-*246quin,9 ACH,10 and Dr. Stephens.11 Under the terms of the agreements, the settling defendants were required to participate in the trial of the case. The agreements also contained pay-back provisions whereby Dr. Syrquin and ACH would be reimbursed for all or part of the settlement money paid to Ms. Smith out of the recovery against Dr. Elbaor.

¶25Dr. Syrquin had performed emergency surgery on Ms. Smith’s ankle. Testimony at trial revealed that Dr. Syrquin, who was not an orthopedic specialist, committed malpractice by closing the ankle too soon after debriding it. Eight days after the surgery, Dr. Syrquin recommended transferring Ms. Smith to ACH where she came under the care of, among others, Dr. Elbaor, an orthopedic specialist. At ACH, Dr. Elbaor observed but did not participate in two additional debridements of Ms. Smith’s ankle which were performed by Dr. Stephens, a plastic surgeon. Dr. Stephens sought to explore and alleviate any infection in Ms. Smith’s ankle. Additional expert medical testimony elicited during the trial demonstrated that, in all probability, Ms. Smith’s ankle was beyond restoration by the time she arrived at ACH. Arguably neither the subsequent surgeries performed at ACH nor the care she received there could have remedied the damage caused by Dr. Syr-quin’s malpractice.

¶26Although the Mary Carter agreements were not entered into evidence, the trial judge was troubled by them and he took remedial measures to mitigate their harmful effects by reapportioning the peremptory challenges, changing the order of proceedings to favor Dr. Elbaor, allowing counsel to explain the agreements to the jury, and instructing the jury regarding the agreements.12

¶27During the trial, the settling defendants’ attorneys, who sat at the table with Dr. Elbaor’s attorneys, vigorously assisted Ms. Smith in pointing the finger of culpability at Dr. Elbaor. This created some odd conflicts of interest and some questionable representations of fact. For example, although Ms. Smith’s own experts testified that Dr. Syrquin committed malpractice, her attorney stated during voir dire and in her opening statement that Dr. Syrquin’s conduct was “heroic” and that Dr. Elbaor’s negligence caused Ms. Smith’s damages. And during her closing argument, Ms. Smith’s attorney urged the jury to find that Dr. Syrquin had not caused Ms. Smith’s damages. This is hardly the kind of statement expected from a plaintiff’s lawyer regarding a named defendant. ACH and Drs. Syrquin and Stephens had remained defendants of record, but their attorneys asserted during voir dire that Ms. Smith’s damages were “devastating," “astoundingly high,” and “astronomical.” Furthermore, on cross examination they elicited testimony from Ms. Smith favorable to her and requested recovery for pain and mental anguish. The settling defendants’ attorneys also abandoned their pleadings on Ms. Smith’s contributory negligence, argued that Ms. Smith should be awarded all of *247her alleged damages, and urged that Dr. Elbaor was 100 percent liable.

¶28A.

¶29The term “Mary Carter agreement” has been defined in different ways by various courts and commentators.13 This Court has yet to definitively define the requisite elements of a Mary Carter agreement — our prior pronouncements utilized different definitions of the term. Compare General Motors Corp. v. Simmons, 558 S.W.2d 855 (Tex.1977) (a Mary Carter agreement is a settlement where the settling defendant remains a party at trial and retains a financial stake in the plaintiffs recovery), overruled on other grounds by Duncan v. Cessna Aircraft Co., 665 S.W.2d 414 (Tex.1984) with Bristol-Myers Co. v. Gonzales, 561 S.W.2d 801, 805 (Tex.1978) (a Mary Carter agreement is a settlement where the settling defendant retains a financial interest in the plaintiffs recovery). Today we clarify what we mean by the term “Mary Carter agreement.” A Mary Carter agreement exists when the settling defendant retains a financial stake in the plaintiff’s recovery and remains a party at the trial of the case.14 This definition comports with both the present majority view15 and the original understanding of the term.16

¶30A Mary Carter agreement exists, under our definition, when the plaintiff enters into a settlement agreement with one defendant and goes to trial against the remaining defendants). The settling defendant, who remains a party, guarantees the plaintiff a minimum payment, which may be offset in whole or in part by an excess judgment recovered at trial. See General Motors Corp. v. Simmons, 558 S.W.2d 855, 858 (Tex.1977), overruled on other grounds by Duncan v. Cessna Aircraft Co., 665 S.W.2d 414, 427 (Tex.1984). This creates a tremendous incentive for the settling defendant to ensure that the plaintiff succeeds in obtaining a sizable recovery, and thus motivates the defendant to assist greatly in the plaintiffs presentation of the case (as occurred here). Indeed, Mary Carter agreements generally, but not always, contain a clause requiring the set*248tling defendant to participate in the trial on the plaintiff’s behalf.

¶31Given this Mary Carter scenario, it is difficult to surmise how these agreements promote settlement. Although the agreements do secure the partial settlement of a lawsuit, they nevertheless nearly always ensure a trial against the non-settling defendant. Bedford School Dist. v. Caron Constr. Co., 116 N.H. 800, 867 A.2d 1051, 1054 (1976) (agreement required plaintiff to prosecute claim against remaining defendant and plaintiff could not settle the claim for under $20,000 without the consent of the settling defendant); Lum v. Stinnett, 87 Nev. 402, 488 P.2d 347, 348 (1971) (same). Mary Carter agreements frequently make litigation inevitable, because they grant the settling defendant veto power over any proposed settlement between the plaintiff and any remaining defendant. See Bass v. Phoenix Seadrill/78 Ltd., 749 F.2d 1154, 1156 (5th Cir.1985) (Mary Carter agreement gave settling defendant veto power). Thus, “[o]nly a mechanical jurisprudence could characterize Mary Carter arrangements as promoting compromise and discouraging litigation — they plainly do just the opposite.” Stein v. American Residential Mgmt., 781 S.W.2d 385, 389 (Tex.App.—Houston [14th Dist.] 1989), writ denied per curiam, 793 S.W.2d 1 (Tex.1990).

¶32In his concurring opinion in Scurlock Oil Co. v. Smithwick, 724 S.W.2d 1, 8 (Tex.1986) (on motion for rehearing), Justice Spears pointed out that “Mary Carter agreements should be prohibited because they are inimical to the adversary system, and they do not promote settlement — their primary justification.” The truth of this statement has been recognized by commentators and has been proven by the subsequent history regarding the use of Mary Carter agreements.17

¶33The dissent approves of the supervisory guidelines suggested in the Smithwickconcurrence, but his opinion misses the point. These guidelines were suggested as a stopgap measure to ameliorate the harmful effects of Mary Carter agreements until this Court finally ruled on the agreements’ propriety. Our inaction has created confusion, because the question as to whether Mary Carter agreements are valid has remained open. See, e.g., Stein, 781 S.W.2d at 388 (“Texas Supreme Court has not passed squarely on the question of [Mary Carter agreements’] validity”); Adams v. Petrade Int’l, Inc., 754 S.W.2d 696, 718 (Tex.App.—Houston [1st Dist.] 1988, writ denied) (“the Texas Supreme Court has not held that such settlements are invalid”); Lubbock Mfg. Co. v. Perez, 591 S.W.2d 907, 920 (Tex.Civ.App.—Waco 1979, dism. agr.) (whether Mary Carter agreements are against public policy is “matter for determination by our Supreme Court of Texas”).

¶34B.

¶35Many jurisdictions have decided to tolerate the ill effects of Mary Carter agreements, presumably because they believe that the agreements promote settlement. Some have sought to mitigate the agreements’ harmful skewing of the trial process by imposing prophylactic protections.18*249Indeed, Texas previously has taken such an approach. See Stein, 781 S.W.2d at 389 (problematic incentives created by Mary Carter agreements require supervisory guidelines enabling trial judges to “keep a short leash on Mary Carter agreements’ potential for wreaking havoc on the civil justice system”); Smithwick, 724 S.W.2d at 8-12 (Spears, J., concurring).19 These protective measures generally seek to remove the secrecy within which Mary Carter agreements traditionally have been shrouded. See Slusher v. Ospital, 777 P.2d 437, 440 (Utah 1989) (secrecy is the essence of a Mary Carter agreement).

¶36Justice Spears rightly noted in Smithwickthe falsity of the premise upon which the prophylactic protection approach is founded, namely, the promotion of equitable settlements. Id. at 8. Mary Carter agreements instead:

present to the jury a sham of adversity between the plaintiff and one co-defendant, while these parties are actually allied for the purpose of securing a substantial judgment for the plaintiff and, in some cases, exoneration for the settling defendant.

¶37June F. Entman, Mary Carter Agreements: An Assessment of Attempted Solutions, 38 U.Fla.L.Rev. 521, 574 (1986); see also General Motors Corp. v. Lahocki, 286 Md. 714, 410 A.2d 1039, 1046 (1980). The agreements pressure the “settling” defendant to alter the character of the suit by contributing discovery material, peremptory challenges, trial tactics, supportive witness examination, and jury influence to the plaintiffs cause. See John E. Benedict, Note, It’s A Mistake to Tolerate the Mary Carter Agreement, 87 Columbia L.Rev. 368, 372-73 (1987). These procedural advantages distort the case presented before a jury that came “to court expecting to see a contest between the plaintiff and the defendants [and] instead see[s] one of the defendants cooperating with the plaintiff.” Smithwick, 724 S.W.2d at 9 (Spears, J., concurring).

¶38Mary Carter agreements not only allow plaintiffs to buy support for their case,20 they also motivate more culpable defendants to “make a ‘good deal’ [and thus] end up paying little or nothing in damages.” Id.; cf. Slayton v. Ford Motor Co., 140 Vt. 27, 435 A.2d 946, 947 (1981) (jury may infer that non-settling defendant was the most culpable defendant because plaintiff did not settle with that defendant). Remedial measures cannot overcome nor sufficiently alleviate the malignant effects that Mary Carter agreements inflict upon our adversarial system. No persuasive public policy justifies them, and they are not legitimized simply because this practice may continue in the absence of these agreements. The Mary Carter agreement is simply an unwise and champertous device that has failed to achieve its intended purpose. See Lum, 488 P.2d at 351 (Mary Carter agreements essentially champertous because settling defendant retains financial interest in plaintiff’s success against non-settling defendant); cf. Monjay v. Evergreen School Dist., 13 Wash.App. 654, 537 P.2d 825, 830 (1975).

¶39IV.

¶40The case before us reveals yet another jury trial and verdict distorted by a Mary Carter agreement. The trial judge, who fully grasped the detrimental effect these agreements could have on the outcome, attempted to monitor the lawsuit by assiduously applying the guidelines suggested in the Smithwickconcurrence. The conduct of this trial, however, confirms the apprehension expressed by Justice Spears in Smithwick: that these remedial measures would only mitigate and not eliminate the unjust influences exerted on a trial by *250Mary Carter agreements. Equalizing peremptory strikes, reordering proceedings, thoroughly disclosing the true alignment of the parties, and revealing the agreement’s substance cannot overcome collusion between the plaintiff and settling defendants who retain a financial interest in the plaintiffs success. In fact, Mary Carter agreements may force attorneys into questionable ethical situations under Rule 3.05 of the Texas Disciplinary Rules of Professional Conduct, which is titled “Maintaining the Impartiality of the Tribunal.” Comment 2 to that rule notes, regarding alternate methods of dispute resolution (like Mary Carter agreements), that “a lawyer should avoid any conduct that is or could reasonably be construed as being intended to corrupt or to unfairly influence the decision-maker.” See SUPREME Court of Texas, Texas Disciplinary Rules of Professional Conduct art. X, § 9 (1990); cf. Model Code of Professional Responsibility EC-720 (1979) (attorneys responsible for upholding adversarial system). The dissent acknowledges that Mary Carter agreements skew the trial process. This effect reasonably could be construed as unfairly influencing the deci-sionmaker.

¶41As a matter of public policy, this Court favors settlements, but we do not favor partial settlements that promote rather than discourage further litigation. And we do not favor settlement arrangements that skew the trial process, mislead the jury, promote unethical collusion among nominal adversaries, and create the likelihood that a less culpable defendant will be hit with the full judgment. The bottom line is that our public policy favoring fair trials outweighs our public policy favoring partial settlements.

¶42This case typifies the kind of procedural and substantive damage Mary Carter agreements can inflict upon our adversarial system. Thus, we declare them void as violative of sound public policy.

¶43However, we do recognize the hardships that our decision today will create on our already burdened courts. Thus, we must decide whether our decision voiding Mary Carter agreements will apply prospectively or retrospectively. Although our decisions usually apply retrospectively, exceptions are recognized when considerations of fairness and policy dictate prospective effect only. Duncan v. Cessna Aircraft Co., 665 S.W.2d 414, 434 (Tex.1984). In Carrollton Farmers Branch Ind. School Dist. v. Edgewood Ind. School Dist., 826 S.W.2d 489, 518-19 (Tex.1992), we adopted the three factors from the United States Supreme Court’s decision in Chevron Oil Co. v. Huson, 404 U.S. 97, 106-07, 92 S.Ct. 349, 355-56, 30 L.Ed.2d 296 (1971) to determine whether to apply a decision prospectively or retroactively. These factors are: (1) whether the decision establishes a new principle of law by either overruling clear past precedent on which litigants may have relied or by deciding an issue of first impression whose resolution was not clearly foreshadowed; (2) whether prospective or retroactive application of the particular rule will further or retard its operation through an examination of the history, purpose, and effect of the rule; and (3) whether retroactive application of the rule could produce substantial inequitable results. Id.

¶44The first and the third of these factors weigh clearly in favor of a determination of prospective application. This case represents an issue of first impression whose resolution was not clearly foreshadowed. Although commentators have routinely criticized the Mary Carter agreement, only a couple of states have previously held that such agreements are void.21 The only Texas opinion which even hinted that such agreements might be void, was Justice Spear’s concurrence in Scurlock Oil Co. v. Smithwick, 724 S.W.2d 1, 8*251(Tex.1986) (on motion for rehearing). Therefore, we conclude that the first factor weighs heavily in favor of prospective application. The third factor likewise weighs heavily in favor of prospective application because retroactive application would create substantial inequitable results for litigants who would have to re-try their cases and re-enter the clogged court dockets of this state when they could not have known that such agreements would be held to be void as against public policy. The second factor favors retroactive application of the rule since the rule is designed to prevent unfair trials resulting from the use of Mary Carter agreements. However, as we discussed in Edgewood, 826 S.W.2d at 519 n. 36, all Chevron factors are not required to favor prospectivity: we engage in a broad balancing of the factors to determine the ultimate considerations of fairness and policy. We conclude that the strength of the first and third factors outweigh the second factor.22 Thus, we declare, as a matter of sound administration and fairness, that this holding shall be applicable only in the present case, to those cases in the judicial pipeline where error has been preserved, and to those actions tried on or after December 2, 1992.23

¶45V.

¶46In short, the evidence in the record creates a fact issue of comparative causation. The jury should have been allowed to pass not only on Drs. Elbaor’s, Syrquin’s, and Stephens’ alleged negligence, but also on Ms. Smith’s alleged negligence. Under this record, the trial court should have left these fact issues for the jury’s resolution within the framework of our well-established comparative negligence law. The failure to submit the issues was calculated to cause, and probably did cause, the rendition of an improper judgment in this case. Tex.R.App.P. 81. The danger in allowing the trial court’s action to stand uncorrected is that this would indicate that patients who refuse to take medication necessary to their recovery are not contributorily negligent even though their unwillingness may have causally contributed to their injuries. Additionally, the judgment in this case was fundamentally driven by Mary Carter agreements. However, because of the existence of a severability clause in some of the agreements but not others and the creation of a financial stake for some defendants in Ms. Smith’s lawsuit but not in others, they must be treated separately.

¶47Agreement between Ms. Smith and Arlington Community Hospital: Because of the severability clause, the portion of the agreement between Ms. Smith and ACH creating ACH’s financial stake in the outcome of the case and requiring ACH to participate in the trial is severed from the rest of the agreement and held null and void.

¶48Agreement between Ms. Smith and Dr. Syrquin: This agreement did not contain a severability clause but Dr. Syr-quin retained a financial state in Ms. Smith’s lawsuit and was required to participate in the trial. The portion of the agreement granting Dr. Syrquin a financial stake in Ms. Smith’s lawsuit is nonetheless held null and void. So as not to interfere with the parties’ right to contract, we leave it to the parties, if they so choose, to develop before the trial court whether this void provision is severable, or whether the entire agreement must fail.

¶49Agreement between Ms. Smith and Dr. Stephens: This agreement did not create a financial stake for Dr. Stephens in *252Ms. Smith’s lawsuit. Thus, this agreement does not meet the test for a Mary Carter agreement.

¶50In summary, a settling defendant may not participate in a trial in which he or she retains a financial interest in plaintiff’s lawsuit. Since Dr. Stephens does not have a financial interest in Ms. Smith’s lawsuit, there is no impediment for him to participate fully in the re-trial of this case as any other party. ACH possesses a financial interest in Ms. Smith’s lawsuit, but it can also participate in the re-trial of the case because we have severed the portion of the agreement creating ACH’s financial stake in the outcome of the case from the remainder of the settlement. Likewise, Dr. Syr-quin does have a financial interest in Ms. Smith’s lawsuit and was required to participate in the trial. We have held the portion of the agreement granting Dr. Syrquin a financial interest in Ms. Smith’s cause of action against Dr. Elbaor null and void. However, his future participation in the retrial of this case has yet to be determined. After a hearing, if the trial court invalidates the entire agreement for lack of consideration or for some other reason, Ms. Smith is obligated to return the settlement funds to Dr. Syrquin and he is free to participate in the re-trial of this cause as any other party. Accordingly, we reverse the judgment of the court of appeals and remand this cause to the trial court for further proceedings consistent with this opinion.